Targeting prostate-specific membrane antigen in prostate cancer.
0/5 보강
APA
Emmett L (2025). Targeting prostate-specific membrane antigen in prostate cancer.. Clinical advances in hematology & oncology : H&O, 23(7), 413-415.
MLA
Emmett L. "Targeting prostate-specific membrane antigen in prostate cancer.." Clinical advances in hematology & oncology : H&O, vol. 23, no. 7, 2025, pp. 413-415.
PMID
41051331 ↗
같은 제1저자의 인용 많은 논문 (3)
- Predictive value of early PSMA upregulation for the response to enzalutamide ± Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
- Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [Lu] Lu-PSMA-617 (ANZUP1901).
- Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.